SCHEMBL983255

SCHEMBL983255

CCCc1ccc[c]c1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SREBF2 Q12772 1/20 0.33
HPGD P15428 3/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
RAB9A P51151 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HTR1A P08908 1/20 0.33
GAA P10253 1/20 0.32
CTSK P43235 1/20 0.31
PPARA Q07869 2/20 0.31
PDCD1 Q15116 1/20 0.31
CD274 Q9NZQ7 1/20 0.31
DPP4 P27487 1/20 0.31
CHRM1 P11229 1/20 0.30
LIPG Q9Y5X9 1/20 0.30
PPARG P37231 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982519 0.89 LIPG (0.39) PPARALIPGPPARG
SCHEMBL981932 0.88 LIPG (0.45) MAPTPPARALIPGPPARG
SCHEMBL983505 0.86 LIPG (0.47) MAPTPPARALIPGPPARG
SCHEMBL17802345 0.86 LIPG (0.47) MAPTPPARALIPGPPARG
SCHEMBL8566183 0.86 LIPG (0.47) MAPTPPARALIPGPPARG
SCHEMBL982140 0.85 GABRA1 (0.35) HPGDSMN1; SMN2MAPTPDCD1CD274
SCHEMBL8562892 0.81 HTR1A (0.41) HPGDALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5800313 0.81 ADRB2 (0.33) HPGDKDM4EALDH1A1
SCHEMBL984059 0.79 KDM4E (0.37) HPGDKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL7703138 0.77 ALDH1A1 (0.34) ALDH1A1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007135527-A2 BENZIMIDAZOLYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2007-11-29 WO claimed
WO-2007135529-A2 AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS PFIZER PRODUCTS INC. (US) 2007-11-29 WO claimed
EP-2275406-B1 PROCESS FOR PRODUCING ISOCYANATE ASAHI CHEMICAL IND (JP) 2018-11-28 EP disclosed
CN-104520348-B Process for producing branched aromatic polycarbonate resin 三菱瓦斯化学株式会社 2017-03-08 CN disclosed
US-9233918-B2 Isocyanate production process ASAHI KASEI CHEMICALS CORPORATION (JP) 2016-01-12 US disclosed
EP-2513125-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOL CARBENE-LIGANDS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2012-10-24 EP disclosed
EP-2493906-A1 HETEROLEPTIC CARBENE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS BASF SE (DE) 2012-09-05 EP disclosed
WO-2011073149-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOL CARBENE-LIGANDS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2011-06-23 WO disclosed
WO-2011051404-A1 HETEROLEPTIC CARBENE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS BASF SE (DE) 2011-05-05 WO disclosed
US-20110092731-A1 ISOCYANATE PRODUCTION PROCESS ASAHI KASEI CHEMICALS CORPORATION (JP) 2011-04-21 US disclosed
EP-2275406-A1 PROCESS FOR PRODUCING ISOCYANATE Asahi Kasei Chemicals Corporation (JP) 2011-01-19 EP disclosed
WO-2007135527-A2 BENZIMIDAZOLYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2007-11-29 WO disclosed
WO-2007135529-A2 AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS PFIZER PRODUCTS INC. (US) 2007-11-29 WO disclosed
US-5596013-A INHIBITORS OF PHOSPHODIESTERASE TYPE IV AND PRODUCTION OF TUMOR NECROSIS FACTOR PFIZER INC (US) 1997-01-21 US disclosed
EP-0738270-A1 DIHYDRO PYRAZOLOPYRROLES PFIZER INC. (US) 1996-10-23 EP disclosed
US-5508300-A INHIBIT PHOSPHODIESTERASE AND PRODUCTION OF TUMOR NECROSIS FACTOR; TREATING INFLAMMATORY DISEASES PFIZER INC. (US) 1996-04-16 US disclosed
WO-1995019362-A1 DIHYDRO PYRAZOLOPYRROLES PFIZER INC. (US) 1995-07-20 WO disclosed
US-4495198-A ELIMINATION OF BETA-BLOCKING ACTIVITY PENNWALT CORPORATION (US) 1985-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092731-A1 ISOCYANATE PRODUCTION PROCESS CPS1, PHGDH, APEH SREBF2 1839/4885HPGD 265/4885KDM4E 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.